{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T17:43:04Z","timestamp":1785433384374,"version":"3.56.0"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,5,18]],"date-time":"2013-05-18T00:00:00Z","timestamp":1368835200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychiatr Q"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s11126-013-9264-4","type":"journal-article","created":{"date-parts":[[2013,5,17]],"date-time":"2013-05-17T09:08:31Z","timestamp":1368781711000},"page":"523-541","source":"Crossref","is-referenced-by-count":10,"title":["Case Reports of Neuroleptic Malignant Syndrome in Context of Quetiapine Use"],"prefix":"10.1007","volume":"84","author":[{"given":"Mark B.","family":"Detweiler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taral R.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kye Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonna G.","family":"Detweiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,5,18]]},"reference":[{"key":"9264_CR1","first-page":"145","volume":"118","author":"J Delay","year":"1960","unstructured":"Delay J, Pichot P, Lemperiere T, et al.: A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychosis. Annales Medico Psychologiques (Paris) 118:145\u2013152, 1960","journal-title":"Annales Medico Psychologiques (Paris)"},{"key":"9264_CR2","first-page":"79","volume":"41","author":"SN Caroff","year":"1980","unstructured":"Caroff SN: The neuroleptic malignant syndrome. Journal of Clinical Psychiatry 41:79\u201383, 1980.","journal-title":"Journal of Clinical Psychiatry"},{"key":"9264_CR3","first-page":"25","volume":"24","author":"SN Caroff","year":"1988","unstructured":"Caroff SN, Mann SC: Neuroleptic malignant syndrome. Psychopharmacology Bulletin 24:25\u201329, 1988","journal-title":"Psychopharmacology Bulletin"},{"key":"9264_CR4","first-page":"62","volume":"24","author":"S Yamawaki","year":"1988","unstructured":"Yamawaki S, Yano E, Terakawa N, et al. Results of second questionnaire about neuroleptic malignant syndrome in Japan (English abstract). Hiroshima Journal of Anesthesia 24:62, 1988","journal-title":"Hiroshima Journal of Anesthesia"},{"key":"9264_CR5","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1192\/S0007125000263125","volume":"175","author":"D Kohen","year":"1999","unstructured":"Kohen D, Bristow MF: Atypical antipsychotics and neuroleptic malignant syndrome. British Journal of Psychiatry 175:392\u2013393, 1999.","journal-title":"British Journal of Psychiatry"},{"key":"9264_CR6","first-page":"395","volume":"53","author":"M Khan","year":"2000","unstructured":"Khan M, Farver D: Recognition, assessment and management of neuroleptic malignant syndrome. South Dakota Journal of Medicine 53:395\u2013400, 2000","journal-title":"South Dakota Journal of Medicine"},{"issue":"suppl 1","key":"9264_CR7","first-page":"S54","volume":"37","author":"S Stubner","year":"2004","unstructured":"Stubner S, Rustenbeck E, Grohmann R, et al.: Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry 37(suppl 1):S54\u2013S64, 2004","journal-title":"Pharmacopsychiatry"},{"issue":"6","key":"9264_CR8","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1176\/appi.ajp.164.6.870","volume":"164","author":"JR Strawn","year":"2007","unstructured":"Strawn JR, Keck PE Jr, Caroff SN: Neuroleptic malignant syndrome. American Journal of Psychiatry 164(6):870\u2013876, 2007.","journal-title":"American Journal of Psychiatry"},{"key":"9264_CR9","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3928\/0048-5713-19910301-05","volume":"21","author":"SN Caroff","year":"1991","unstructured":"Caroff SN, Mann SC, Lazarus A, et al.: Neuroleptic malignant syndrome: diagnostic issues. Psychiatric Annales 21:130\u2013147, 1991","journal-title":"Psychiatric Annales"},{"key":"9264_CR10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0025-7125(16)30278-4","volume":"77","author":"SN Caroff","year":"1993","unstructured":"Caroff SN, Mann SC: Neuroleptic malignant syndrome. Medical Clinics of North America, 77:185\u2013202, 1993","journal-title":"Medical Clinics of North America"},{"key":"9264_CR11","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/10401230600801259","volume":"18","author":"KR Kaufman","year":"2006","unstructured":"Kaufman KR, Levitt MJ, Schiltz JF, et al.: Neuroleptic malignant syndrome and serotonin syndrome in the critical care setting: Case analysis. Annals of Clinical Psychiatry 18:201\u2013204, 2006","journal-title":"Annals of Clinical Psychiatry"},{"key":"9264_CR12","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1001\/archinte.1991.00400040130031","volume":"151","author":"DL Keyser","year":"1991","unstructured":"Keyser DL, Rodnitzky RL: Neuroleptic malignant syndrome in Parkinson\u2019s disease after withdrawal or alteration of dopaminergic therapy. The Archives of Internal Medicine 151:794\u2013796, 1991","journal-title":"The Archives of Internal Medicine"},{"key":"9264_CR13","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1345\/aph.1A440","volume":"36","author":"ML Lu","year":"2002","unstructured":"Lu ML, Pan JJ, HW Teng HW, et al.: Metoclopramide-induced super sensitivity psychosis. The Annals of Pharmacotherapy 36:1387\u20131390, 2002","journal-title":"The Annals of Pharmacotherapy"},{"key":"9264_CR14","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2174\/157488609787354387","volume":"4","author":"Y Odagaki","year":"2009","unstructured":"Odagaki Y: Atypical neuroleptic malignant syndrome or serotonin toxicity associated with atypical antipsychotics? Current Drug Safety 4:84\u201393, 2009","journal-title":"Current Drug Safety"},{"key":"9264_CR15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00002826-198406000-00001","volume":"7","author":"R Kurlan","year":"1984","unstructured":"Kurlan R. Hamill R, Shoulson I: Neuroleptic malignant syndrome. Clinical Neuropharmacology 7:109\u2013120, 1984","journal-title":"Clinical Neuropharmacology"},{"key":"9264_CR16","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1176\/ajp.142.10.1137","volume":"142","author":"JL Levenson","year":"1985","unstructured":"Levenson JL: Neuroleptic malignant syndrome. American Journal of Psychiatry 142:1137\u20131145, 1985","journal-title":"American Journal of Psychiatry"},{"key":"9264_CR17","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1176\/ajp.143.12.1587","volume":"143","author":"G Addonizio","year":"1986","unstructured":"Addonizio G, Susman VI, Roth SD: Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients. American Journal of Psychiatry 143:1587\u20131590, 1986","journal-title":"American Journal of Psychiatry"},{"key":"9264_CR18","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1176\/ajp.143.10.1227","volume":"143","author":"HG Pope","year":"1986","unstructured":"Pope HG, Keck PE, McElroy SL: Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. American Journal of Psychiatry 143:1227\u20131233, 1986","journal-title":"American Journal of Psychiatry"},{"key":"9264_CR19","first-page":"328","volume":"48","author":"HH Harsch","year":"1987","unstructured":"Harsch HH: Neuroleptic malignant syndrome: Physiological and laboratory findings in a series of nine cases. Journal of Clinical Psychiatry 48:328\u2013333, 1987","journal-title":"Journal of Clinical Psychiatry"},{"key":"9264_CR20","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00002826-198808000-00006","volume":"11","author":"JH Friedman","year":"1988","unstructured":"Friedman JH, Davis R, Wagner RL: Neuroleptic malignant syndrome: The results of a 6-month prospective study of incidence in a state psychiatric hospital. Clinical Neuropharmacology 11:373\u2013377, 1988","journal-title":"Clinical Neuropharmacology"},{"key":"9264_CR21","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1097\/00005053-199010000-00010","volume":"178","author":"MD Warner","year":"1990","unstructured":"Warner MD, Peabodt CA, Boutros NN: A survey of neuroleptic malignant syndrome. Journal of Nervous and Mental Disease 178:664\u2013665, 1990","journal-title":"Journal of Nervous and Mental Disease"},{"key":"9264_CR22","volume-title":"Diagnostic and Statistical Manual of Mental Disorders, 4th edn, Text Revision","author":"American Psychiatric Association","year":"2000","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn, Text Revision. Washington, DC, American Psychiatric Association, 2000"},{"key":"9264_CR23","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1192\/bjp.153.1.107","volume":"153","author":"Adityanjee","year":"1988","unstructured":"Adityanjee, Singh S, Singh G, Ong S: Spectrum concept of neuroleptic malignant syndrome. British Journal of Psychiatry 153:107\u2013111, 1988","journal-title":"British Journal of Psychiatry"},{"key":"9264_CR24","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1017\/S1461145799001388","volume":"2","author":"Adityanjee","year":"1999","unstructured":"Adityanjee, Mathews T, Aderibigbe YA: Proposed research diagnostic criteria for neuroleptic malignant syndrome. International Journal of Neuropsychopharmacology 2:129\u2013144,1999","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"9264_CR25","doi-asserted-by":"crossref","unstructured":"Gurrera RJ, Caroff SN, Cohen A, et al: An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. Journal of Clinical Psychiatry 72:1222\u201312228, 2011","DOI":"10.4088\/JCP.10m06438"},{"key":"9264_CR26","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1176\/ajp.155.8.1113","volume":"155","author":"S Hasan","year":"1998","unstructured":"Hasan S, Buckley P: Novel antipsychotics and the neuroleptic malignant syndrome: A review and critique. American Journal of Psychiatry 155:1113\u20131116, 1998","journal-title":"American Journal of Psychiatry"},{"key":"9264_CR27","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3928\/0048-5713-20000501-09","volume":"30","author":"SN Caroff","year":"2000","unstructured":"Caroff SN, Mann SC, Campbell EC: Atypical antipsychotics and neuroleptic malignant syndrome. Psychiatric Annals 30:314\u2013321, 2000","journal-title":"Psychiatric Annals"},{"key":"9264_CR28","doi-asserted-by":"crossref","first-page":"464","DOI":"10.4088\/JCP.v65n0403","volume":"65","author":"J Ananth","year":"2004","unstructured":"Ananth J, Parameswaran S, Gunatilake S, et al.: Neuroleptic malignant syndrome and atypical antipsychotic drugs. Journal of Clinical Psychiatry 65:464\u2013470, 2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"9264_CR29","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S0893-133X(99)00129-3","volume":"22","author":"B McEwan","year":"2000","unstructured":"McEwan B: Allostasis and allostatic load. Implication for neuropsychopharmacology. Neuropsychopharmacology 22:108\u2013124, 2000","journal-title":"Neuropsychopharmacology"},{"key":"9264_CR30","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003495-200161010-00011","volume":"61","author":"N Bhana","year":"2001","unstructured":"Bhana N, Foster RH, Olney R, et al.: Olanzapine: An updated review of its use in the management of schizophrenia. Drugs 61:111\u2013161, 2001","journal-title":"Drugs"},{"key":"9264_CR31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1517\/14740338.2.1.21","volume":"2","author":"DK Farver","year":"2003","unstructured":"Farver DK: Neuroleptic malignant syndrome induced by atypical antipsychotics. Expert Opinion on Drug Safety 2:21\u201335, 2003","journal-title":"Expert Opinion on Drug Safety"},{"key":"9264_CR32","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1592\/phco.22.8.641.33211","volume":"22","author":"RR Reeves","year":"2002","unstructured":"Reeves RR, Torres RA, Liberto V, et al.: Atypical neuroleptic syndrome associated with olanzapine. Pharmacotherapy 22:641\u2013644, 2002","journal-title":"Pharmacotherapy"},{"issue":"suppl 2","key":"9264_CR33","first-page":"5","volume":"65","author":"GS Alexopoulos","year":"2004","unstructured":"Alexopoulos GS, Streim JE, Carpenter D, et al.: Using antipsychotic agents in older patients. Journal of Clinical Psychiatry 65(suppl 2):5\u2013104, 2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"9264_CR34","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/0006-3223(87)90010-2","volume":"22","author":"G Addonizio","year":"1987","unstructured":"Addonizio G, Susman VL, Roth SD: Neuroleptic malignant syndrome: Review and analysis of 115 cases. Biological Psychiatry 22:1004\u20131020, 1987","journal-title":"Biological Psychiatry"},{"key":"9264_CR35","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1176\/appi.ajp.159.1.149","volume":"159","author":"KJ Sing","year":"2002","unstructured":"Sing KJ, Ramaekers GM, Van Harten PN: Neuroleptic malignant syndrome and quetiapine. American Journal of Psychiatry 159:149\u2013150, 2002","journal-title":"American Journal of Psychiatry"},{"key":"9264_CR36","first-page":"112","volume":"52","author":"N Whalley","year":"1999","unstructured":"Whalley N, Diaz P, Howard J. Neuroleptic malignant syndrome associated with the use of quetiapine (letter). Canadian Journal of Hospital Pharmacy 52:112, 1999","journal-title":"Canadian Journal of Hospital Pharmacy"},{"key":"9264_CR37","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1176\/appi.ajp.162.4.812","volume":"162","author":"R Matsumoto","year":"2005","unstructured":"Matsumoto R, Kitabayashi Y, Nakatomi Y, et al: Neuroleptic malignant syndrome induced by quetiapine and fluvoxamine. American Journal of Psychiatry 162:812, 2005","journal-title":"American Journal of Psychiatry"},{"key":"9264_CR38","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1440-1819.2008.01921.x","volume":"63","author":"A Dan","year":"2009","unstructured":"Dan A, Bharadwaj R, Grover S: Neuroleptic malignant syndrome with use of quetiapine in mental retardation. Psychiatry and Clinical Neurosciences 63:255\u2013256, 2009","journal-title":"Psychiatry and Clinical Neurosciences"},{"key":"9264_CR39","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.pnpbp.2006.04.001","volume":"30","author":"A Kobayashi","year":"2006","unstructured":"Kobayashi A, Kawanishi C, Matsumura T, et al.: Quetiapine-induced neuroleptic malignant syndrome in dementia with Lewy bodies: A case report. Progress in Neuro-Psychopharmacology & Biological Psychiatry 30:1170\u20131172, 2006","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"key":"9264_CR40","doi-asserted-by":"crossref","first-page":"16","DOI":"10.17986\/blm.2009141685","volume":"14","author":"TS Lai","year":"2009","unstructured":"Lai TS, Lam SM: Quetiapine induced neuroleptic malignant syndrome. The Hong Kong medical diary. Medical Bulletin 14:16\u201318, 2009","journal-title":"Medical Bulletin"},{"key":"9264_CR41","doi-asserted-by":"crossref","first-page":"171","DOI":"10.12968\/hmed.2008.69.3.28758","volume":"69","author":"KH Khan","year":"2008","unstructured":"Khan KH, Tham TC: Neuroleptic malignant syndrome induced by quetiapine overdose. British Journal of Hospital Medicine 69:171, 2008","journal-title":"British Journal of Hospital Medicine"},{"key":"9264_CR42","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1192\/bjp.176.5.497-a","volume":"176","author":"AK Stanley","year":"2000","unstructured":"Stanley AK, Hunter J: Possible neuroleptic malignant syndrome with quetiapine. British Journal of Psychiatry 176:497, 2000","journal-title":"British Journal of Psychiatry"},{"key":"9264_CR43","doi-asserted-by":"crossref","unstructured":"Solomons K: Quetiapine and neuroleptic malignant syndrome. Canadian Journal of Psychiatry 47:791, 2002","DOI":"10.1177\/070674370204700826"},{"key":"9264_CR44","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1176\/appi.neuropsych.14.1.87","volume":"14","author":"JA Bourgeois","year":"2002","unstructured":"Bourgeois JA, Babine S, Meyerovish M, et al.: A case of neuroleptic malignant syndrome with quetiapine. Journal of Neuropsychiatry & Clinical Neurosciences 14:87, 2002","journal-title":"Journal of Neuropsychiatry & Clinical Neurosciences"},{"key":"9264_CR45","doi-asserted-by":"crossref","unstructured":"Gortney JS, Fagan A, Kissack J: Neuroleptic malignant syndrome secondary to quetiapine. Annals of Pharmacotherapy 43:785\u2013791, 2009","DOI":"10.1345\/aph.1L371"},{"key":"9264_CR46","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1097\/01.jcp.0000145346.61041.18","volume":"24","author":"SG Sugden","year":"2004","unstructured":"Sugden SG, Bourgeois JA, Kile SJ, et al.: Neuroleptic malignant syndrome with dermatologic complications. Journal of Clinical Psychopharmacology 24:676\u2013678, 2004","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"9264_CR47","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/mds.20749","volume":"21","author":"K Suzuki","year":"2006","unstructured":"Suzuki K, Awata S, Nakagawa K, et al.: Catatonic stupor during the course of Parkinson\u2019s disease resolved with electroconvulsive therapy. Movement Disorders 21:123\u2013130, 2006","journal-title":"Movement Disorders"},{"key":"9264_CR48","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1177\/0269881105053310","volume":"19","author":"DS Chungh","year":"2005","unstructured":"Chungh DS, Kim BN, Cho SC: Neuroleptic malignant syndrome due to three atypical antipsychotics in a child. Journal of Psychopharmacology 19:422\u2013425, 2005","journal-title":"Journal of Psychopharmacology"},{"key":"9264_CR49","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1080\/13651500510029110","volume":"9","author":"S Grignon","year":"2005","unstructured":"Grignon S, Brethes JI, Chamberland M, et al.: Incipient neuroleptic malignant syndrome with quetiapine\/paroxetine combination treatment: Atypical presentation and early, successful rechallenge with olanzapine. International Journal of Psychiatry in Clinical Practice 9:296\u2013298, 2005","journal-title":"International Journal of Psychiatry in Clinical Practice"},{"key":"9264_CR50","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1017\/S1481803500014421","volume":"7","author":"DP Seitz","year":"2005","unstructured":"Seitz DP: Diagnostic uncertainty in a case of neuroleptic malignant syndrome. Canadian Journal of Emergency Medicine 7:266\u2013272, 2005","journal-title":"Canadian Journal of Emergency Medicine"},{"key":"9264_CR51","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/clpt.1991.184","volume":"50","author":"D Nierenberg","year":"1991","unstructured":"Nierenberg D, Disch M, Manheimer E, et al.: Facilitating prompt diagnosis and treatment of the neuroleptic malignant syndrome. Clinical Pharmacology & Therapeutics 50:580\u2013586, 1991","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"9264_CR52","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00004714-199510000-00010","volume":"15","author":"P Sachdev","year":"1995","unstructured":"Sachdev P, Kruk J, Kneebone M, et al.: Clozapine-induced neuroleptic malignant syndrome: Review and report of new cases. Journal of Clinical Psychopharmacology 15:365\u2013371, 1995","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"9264_CR53","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1176\/ajp.154.8.1156","volume":"154","author":"P Sachdev","year":"1997","unstructured":"Sachdev P, Mason C, Hadzi-Pavlovic D: Case\u2013control study of neuroleptic malignant syndrome. American Journal of Psychiatry 154:1156\u20131158, 1997","journal-title":"American Journal of Psychiatry"},{"key":"9264_CR54","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0736-4679(94)90012-4","volume":"12","author":"R Lev","year":"1994","unstructured":"Lev R, Clark RF. Neuroleptic malignant syndrome presenting without fever: Case report and review of the literature. Journal of Emergency Medicine 12:49\u201355, 1994","journal-title":"Journal of Emergency Medicine"},{"issue":"Suppl 1","key":"9264_CR55","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/PL00014200","volume":"251","author":"M Fink","year":"2001","unstructured":"Fink M, Taylor MA: The many varieties of catatonia. European Archives of Psychiatry and Clinical Neuroscience 251(suppl 1):8\u201313, 2001","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"key":"9264_CR56","doi-asserted-by":"crossref","unstructured":"Pr\u00e9court A, Dunewicz M, Gr\u00e9goire G, et al.: Multiple complications and withdrawal syndrome associated with quetiapine\/venlafaxine intoxication. Annals of Pharmacotherapy 39:153\u2013156, 2005","DOI":"10.1345\/aph.1E073"},{"key":"9264_CR57","volume-title":"The Neuroleptic Malignant Syndrome and Related Conditions","author":"A Lazarus","year":"1998","unstructured":"Lazarus A, Mann SC, Caroff SN. The Neuroleptic Malignant Syndrome and Related Conditions. Washington, DC, American Psychiatric Press, 1998"},{"key":"9264_CR58","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/archpsyc.1989.01810100056011","volume":"46","author":"PE Keck Jr","year":"1989","unstructured":"Keck PE Jr, Pope HG Jr, Cohen BM, et al.: Risk factors for neuroleptic malignant syndrome. Archives General Psychiatry 46:914\u2013918, 1989","journal-title":"Archives General Psychiatry"},{"key":"9264_CR59","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/gps.930060310","volume":"6","author":"FN Nicklason","year":"1991","unstructured":"Nicklason FN, Finucane PM, Pathy MJ, et al.: Neuroleptic malignant syndrome: An unrecognized problem in elderly patients with psychiatric illness? International Journal of Geriatric Psychiatry 6:171\u2013175, 1991","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"9264_CR60","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(94)90542-8","volume":"344","author":"P Webster","year":"1994","unstructured":"Webster P, Wijeratne C: Risperidone-induced neuroleptic malignant syndrome. Lancet 344:1228\u20131229, 1994","journal-title":"Lancet"},{"key":"9264_CR61","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0749-0704(05)70368-7","volume":"13","author":"KC Mills","year":"1997","unstructured":"Mills KC. Serotonin syndrome. A clinical update. Critical Care Clinics 13:763\u2013783, 1997","journal-title":"Critical Care Clinics"},{"key":"9264_CR62","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/gps.930071112","volume":"7","author":"Adityanjee","year":"1992","unstructured":"Adityanjee, Jayaswal SK, Chant SP, et al.: Case report: Neuroleptic malignant syndrome in an elderly patient: Problems in management. International Journal of Geriatric Psychiatry 7:843\u2013846, 1992","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"9264_CR63","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF01250797","volume":"90","author":"T Becker","year":"1992","unstructured":"Becker T, Kornhuber J, Hofmann E, et al.: MRI white matter hyperintensity in neuroleptic malignant syndrome (NMS)\u2014A clue to pathogenesis? Journal of Neural Transmission 90:151\u2013159, 1992","journal-title":"Journal of Neural Transmission"},{"key":"9264_CR64","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/jnnp.2005.081133","volume":"76","author":"S Cooper","year":"2005","unstructured":"S Cooper S, Greene JDW: The clinical assessment of the patient with early dementia. Journal of Neurology, Neurosurgery, and Psychiatry 76:15\u201324, 2005","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"9264_CR65","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1126\/science.6334363","volume":"226","author":"DF Wong","year":"1984","unstructured":"Wong DF, Wagner HN, Dannals RF, et al.: Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain. Science 226:1393\u20131396, 1984","journal-title":"Science"},{"key":"9264_CR66","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1532-5415.1986.tb07266.x","volume":"34","author":"M Serby","year":"1986","unstructured":"Serby M: Neuroleptic malignant syndrome in Alzheimer\u2019s disease. Journal of the American Geriatrics Society 34:895\u2013896, 1986","journal-title":"Journal of the American Geriatrics Society"},{"key":"9264_CR67","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.eurpsy.2003.07.001","volume":"18","author":"E Bora","year":"2003","unstructured":"Bora E, Gonul S, Akdeniz F, Vahip S. Neuroleptic malignant-like syndrome induced with low-dose quetiapine treated with electroconvulsive therapy. European Psychiatry 18:323, 2003","journal-title":"European Psychiatry"},{"key":"9264_CR68","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1176\/ajp.147.9.1149","volume":"147","author":"MZ Deng","year":"1990","unstructured":"Deng MZ, Chen GQ, Phillips MR: Neuroleptic malignant syndrome in 12 of 9,792 Chinese patients exposed to neuroleptics: A prospective study. American Journal of Psychiatry 147:1149\u20131155, 1990","journal-title":"American Journal of Psychiatry"},{"key":"9264_CR69","first-page":"941","volume":"45","author":"N Aydin","year":"2000","unstructured":"Aydin N, Anac E, Caykoylu A, Akcay F: Neuroleptic malignant syndrome due to citalopram overdose. Canadian Journal of Psychiatry 45:941\u2013942, 2000","journal-title":"Canadian Journal of Psychiatry"},{"key":"9264_CR70","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/0010-440X(86)90002-7","volume":"27","author":"P Hamburg","year":"1986","unstructured":"Hamburg P, Weilburg JB, Cassem NH, et al.: Relapse of neuroleptic malignant syndrome with early discontinuation of amantadine therapy. Comprehensive Psychiatry 27:272\u2013275, 1986","journal-title":"Comprehensive Psychiatry"},{"key":"9264_CR71","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s004310100743","volume":"160","author":"T Ito","year":"2001","unstructured":"Ito T, Shibata K, Watanabe A, Akabane J: Neuroleptic malignant syndrome following withdrawal of amantadine in a patient with influenza A encephalopathy. European Journal of Pediatrics 160:401, 2001","journal-title":"European Journal of Pediatrics"},{"key":"9264_CR72","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1002\/mds.22359","volume":"24","author":"EJ Newman","year":"2009","unstructured":"Newman EJ, Kieran Breen K, Patterson J, et al.: Accuracy of Parkinson\u2019s disease diagnosis in 610 general practice patients in the West of Scotland. Movement Disorders 24:2379\u20132385, 2009","journal-title":"Movement Disorders"},{"key":"9264_CR73","unstructured":"Bilbao Garay J, Mesa Plaza N, Castilla Castellano V, et al.: Serotonin syndrome: Report of a fatal case and review of the literature. Revista Cl\u00ednica Espa\u00f1ola 202:209\u2013211, 2002 (Article in Spanish)"},{"key":"9264_CR74","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s004150070101","volume":"247","author":"NP Hinds","year":"2000","unstructured":"Hinds NP, Hillier CE, Wiles CM: Possible serotonin syndrome arising from an interaction between nortriptyline and selegiline in a lady with parkinsonism. Journal of Neurology 247:811, 2000","journal-title":"J Neurol."},{"key":"9264_CR75","unstructured":"FDA ALERT [7\/2006]: Potentially Life-Threatening Serotonin Syndrome with Combined Use of SSRIs or SNRIs and Triptan Medications http:\/\/www.fda.gov\/drugs\/drugsafety\/postmarketdrugsafetyinformationforpatientsandproviders\/ucm125925.htm . Accessed March 12, 2012"},{"key":"9264_CR76","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1176\/appi.ajp.158.12.2088","volume":"158","author":"RE McCue","year":"2001","unstructured":"McCue RE Joseph M: Venlafaxine- and trazodone-induced serotonin syndrome. American Journal of Psychiatry 158:2088\u20132089, 2001","journal-title":"American Journal of Psychiatry"},{"key":"9264_CR77","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1345\/aph.17041","volume":"32","author":"VS Bhatara","year":"1998","unstructured":"Bhatara VS, Magnus RD, Paul KL, et al: serotonin syndrome induced by venlafaxine and fluoxetine: A case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms. Annals of Pharmacotherapy 32:432\u2013436, 1998","journal-title":"Annals of Pharmacotherapy"},{"key":"9264_CR78","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0196-0644(97)70283-X","volume":"29","author":"JL Leela","year":"1997","unstructured":"Leela JL, Perreault MM, Tao T, et al.: Serotonin syndrome associated with nefazodone and paroxetine. Annals of Emergency Medicine 29:287\u2013289, 1997","journal-title":"Annals of Emergency Medicine"},{"key":"9264_CR79","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1345\/aph.1D352","volume":"38","author":"LI Velez","year":"2004","unstructured":"Velez LI, Shepherd G, Roth BA, et al.: Serotonin syndrome with elevated paroxetine concentrations. Annals of Pharmacotherapy 38:269\u2013272, 2004","journal-title":"Annals of Pharmacotherapy"},{"key":"9264_CR80","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/JCP.0b013e3181b4b091","volume":"29","author":"S El-Gaaly","year":"2009","unstructured":"El-Gaaly S, St John P, Dunsmore S, et al.: Atypical neuroleptic malignant syndrome with quetiapine: A case report and review of literature. Journal of Clinical Psychopharmacology 29:497\u2013499, 2009","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"9264_CR81","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1176\/appi.ajp.161.6.1129","volume":"161","author":"R Mahlberg","year":"2004","unstructured":"Mahlberg R, Kunz D, Sasse J, Kircheiner J: Serotonin syndrome with tramadol and citalopram. American Journal of Psychiatry 161:1129, 2004","journal-title":"American Journal of Psychiatry"},{"key":"9264_CR82","first-page":"76","volume":"4","author":"BHW Cheng","year":"2009","unstructured":"Cheng BHW, Mok WWY. Serotonin syndrome after taking citalopram. Asian Journal of Gerontology and Geriatrics 4:76\u201378, 2009","journal-title":"Asian Journal of Gerontology and Geriatrics"},{"key":"9264_CR83","first-page":"59","volume":"119","author":"K Marlowe","year":"2006","unstructured":"Marlowe K, Schirgel D: Quetiapine and citalopram: Aetiological significance in serotonin syndrome. New Zealand Medical Journal 119:59\u201362, 2006","journal-title":"New Zealand Medical Journal"},{"key":"9264_CR84","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0924-977X(96)00043-0","volume":"7","author":"D Ebert","year":"1997","unstructured":"Ebert D, Albert R, May A, et al.: The serotonin syndrome and psychosis-like side-effects of fluvoxamine in clinical use\u2014An estimation of incidence. European Neuropsychopharmacology 7:71\u201374, 1997","journal-title":"European Neuropsychopharmacology"},{"key":"9264_CR85","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1345\/aph.10418","volume":"35","author":"JC Demers","year":"2001","unstructured":"Demers JC, Malone M: Serotonin syndrome induced by fluvoxamine and mirtazapine. Annals of Pharmacotherapy 35:1217\u20131220, 2001","journal-title":"Annals of Pharmacotherapy"},{"key":"9264_CR86","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3109\/00207450108986532","volume":"109","author":"Y Kaneda","year":"2001","unstructured":"Kaneda Y, Ishimoto Y, Ohmori T: Mild serotonin syndrome on fluvoxamine. International Journal of Neuroscience 109:165\u2013172, 2001","journal-title":"International Journal of Neuroscience"},{"key":"9264_CR87","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0887-8994(98)00045-9","volume":"19","author":"H Ehara","year":"1998","unstructured":"Ehara H, Maegaki Y, Takeshita K: Neuroleptic malignant syndrome and methylphenidate. Pediatric Neurology 19:299\u2013301, 1998","journal-title":"Pediatric Neurology"},{"key":"9264_CR88","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4088\/PCC.v08n0109a","volume":"8","author":"B Basil","year":"2006","unstructured":"Basil B, Mathews M, Budur K: Methylphenidate-induced neuroleptic malignant syndrome: A case report. Primary Care Companion To the Journal of Clinical Psychiatr 8:47, 2006","journal-title":"Primary Care Companion To the Journal of Clinical Psychiatry"},{"key":"9264_CR89","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1440-1819.2008.01767.x","volume":"62","author":"M Ishii","year":"2008","unstructured":"Ishii M, Tatsuzawa Y, Yoshino A, et al.: Serotonin syndrome induced by augmentation of SSRI with methylphenidate. Psychiatry and Clinical Neurosciences 62:246, 2008","journal-title":"Psychiatry and Clinical Neurosciences"},{"key":"9264_CR90","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/00004714-198710000-00010","volume":"7","author":"VL Susman","year":"1987","unstructured":"Susman VL, Addonizio G: Reinduction of neuroleptic malignant syndrome by lithium. Journal of Clinical Psychopharmacology 7:339\u2013341, 1987","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"9264_CR91","unstructured":"Brown CH: Drug-induced serotonin syndrome. US Pharm 35(11):HS-16\u2013HS-21, 2010"},{"key":"9264_CR92","first-page":"267P","volume":"60","author":"CJ Carter","year":"1977","unstructured":"Carter CJ, Pycock CJ: Possible importance of hydroxytryptamine in neuroleptic-induced catalepsy in rats [proceedings]. British Journal of Pharmacology 60:267P\u2013268P, 1977","journal-title":"British Journal of Pharmacology"},{"key":"9264_CR93","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/archpsyc.1990.01810140091015","volume":"47","author":"RJ Baldessarini","year":"1990","unstructured":"Baldessarini RJ, March E: Fluoxetine and side effects. Archives of General Psychiatry 47:191\u2013192, 1990","journal-title":"Archives of General Psychiatry"},{"key":"9264_CR94","first-page":"295","volume":"50","author":"PI Rosebush","year":"1989","unstructured":"Rosebush PI, Stewart TD, Gelenberg AJ: Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients. Journal of Clinical Psychiatry 50:295\u2013298, 1989","journal-title":"Journal of Clinical Psychiatry"},{"key":"9264_CR95","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/0006-3223(90)90002-J","volume":"27","author":"K Nisijima","year":"1991","unstructured":"Nisijima K, Ishiguro T: Neuroleptic malignant syndrome: A study of CSF monoamine metabolism. Biological Psychiatry 27:280\u2013288, 1991","journal-title":"Biological Psychiatry"},{"key":"9264_CR96","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1034\/j.1600-0447.2003.02385.x","volume":"107","author":"LF Viejo","year":"2003","unstructured":"Viejo LF, Morales V, Pu\u00f1al P, et al.: Risk factors in neuroleptic malignant syndrome. A case\u2013control study. Acta Psychiatrica Scandinavica 107:45\u201349, 2003","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"9264_CR97","first-page":"143","volume":"98","author":"RD Boyd","year":"1993","unstructured":"Boyd RD. Neuroleptic malignant syndrome and mental retardation: Review and analysis of 29 cases. American Journal of Mental Retardation 98:143\u2013155, 1993","journal-title":"American Journal of Mental Retardation"},{"key":"9264_CR98","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1176\/ajp.156.7.1115a","volume":"156","author":"HC Margolese","year":"1999","unstructured":"Margolese HC, Chouinard G: Olanzapine-induced neuroleptic malignant syndrome. American Journal of Psychiatry 156:1115a-6, 1999","journal-title":"American Journal of Psychiatry"},{"key":"9264_CR99","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.pnpbp.2006.04.006","volume":"30","author":"T Tanii","year":"2006","unstructured":"Tanii T, Ichihashi K, Inoue K, et al.: Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam. Progress in Neuro-Psychopharmacology & Biological Psychiatry 30:1176\u20131178, 2006a","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"key":"9264_CR100","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00004714-198610000-00002","volume":"6","author":"CA Pearlman","year":"1986","unstructured":"Pearlman CA: Neuroleptic malignant syndrome: A review of the literature. Journal of Clinical Psychopharmacology 6:257\u2013273, 1986","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"9264_CR101","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1192\/bjp.159.4.572","volume":"159","author":"LS Chong","year":"1991","unstructured":"Chong LS, Abbott PM: Neuroleptic malignant syndrome secondary to loxapine. British Journal of Psychiatry 159:572\u2013573, 1991","journal-title":"British Journal of Psychiatry"},{"key":"9264_CR102","first-page":"439","volume":"169","author":"J Geethan","year":"2003","unstructured":"Geethan J, Chandran GJ, Mikler JR, et al.: Neuroleptic malignant syndrome: Case report and discussion. CMAJ 169:439\u2013442, 2003","journal-title":"CMAJ"},{"key":"9264_CR103","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1136\/jnnp.51.8.1109","volume":"51","author":"K Kashihara","year":"1988","unstructured":"Kashihara K, Ishida K: Neuroleptic malignant syndrome due to sulpiride. Journal of Neurology, Neurosurgery, and Psychiatry 51:1109\u20131110, 1988","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"9264_CR104","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1177\/0269881109359097","volume":"25","author":"M Peet","year":"2011","unstructured":"Peet M, Collier J: A naturalistic controlled study of relapsing schizophrenic patients with tardive dyskinesia and supersensitivity psychosis. Journal of Psychopharmacology 25:755\u2013762, 2011","journal-title":"Journal of Psychopharmacology"},{"key":"9264_CR105","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/10601338609032954","volume":"4","author":"SJ Matthews","year":"1986","unstructured":"Matthews SJ, Cersosimo RJ: Haloperidol induced neuroleptic malignant syndrome. Clinical Research and Regulatory Affairs 4:33\u201341, 1986","journal-title":"Clinical Research and Regulatory Affairs"},{"key":"9264_CR106","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1080\/026990599121034","volume":"13","author":"R Wilkinson","year":"1999","unstructured":"Wilkinson R, Meythaler JM, Guin-Renfore S: Neuroleptic malignant syndrome induced by haloperidol following traumatic brain injury. Brain Injury 13:1025\u20131031, 1999","journal-title":"Brain Injury"},{"key":"9264_CR107","first-page":"211","volume":"39","author":"T Mahmood","year":"1989","unstructured":"Mahmood T, Warren JP: Neuroleptic malignant syndrome from chlorpromazine: Case report. Journal of Royal College of General Practitioners 39:211, 1989","journal-title":"Journal of Royal College of General Practitioners"},{"key":"9264_CR108","unstructured":"RxMed: Pharmaceutical Information: Chlorpromazine General Monograph http:\/\/www.rxmed.com\/b.main\/b2.pharmaceutical\/b2.1.monographs\/CPS-Monographs\/CPS-(GeneralMonographs-C)\/CHLORPROMAZINE.html . Accessed 2.22.2012."},{"key":"9264_CR109","first-page":"51","volume":"6","author":"V Khaldarov","year":"2000","unstructured":"Khaldarov V: Benzodiazepines for treatment of neuroleptic malignant syndrome. Hospital Physician 6:51\u201355, 2000","journal-title":"Hospital Physician"},{"key":"9264_CR110","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1080\/j.1440-1614.2000.0766g.x","volume":"34","author":"R Mahendran","year":"2000","unstructured":"Mahendran R, Winslow M, Lim D: Recurrent neuroleptic malignant syndrome. Australian and New Zealand Journal of Psychiatry 34:699\u2013700, 2000","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"key":"9264_CR111","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/hup.250","volume":"16","author":"MS Arnaout","year":"2001","unstructured":"Arnaout MS, Antun FP, Ashkar K: Neuroleptic malignant syndrome with olanzapine associated with severe hypernatremia. Human Psychopharmacology Clinical and Experimental 16:279\u2013281, 2001","journal-title":"Human Psychopharmacology Clinical and Experimental"},{"key":"9264_CR112","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1600-0447.2005.00578.x","volume":"112","author":"J Nielsen","year":"2005","unstructured":"Nielsen J, Bruhn AM: Atypical neuroleptic malignant syndrome caused by olanzapine. Acta Psychiatrica Scandinavica 112:238\u2013240, 2005","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"9264_CR113","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1592\/phco.26.8.1180","volume":"26","author":"NB Norgard","year":"2006","unstructured":"Norgard NB, Jennifer E Stark JE: Olanzapine-associated neuroleptic malignant syndrome. Pharmacotherapy 26:1180\u20131182, 2006","journal-title":"Pharmacotherapy"},{"key":"9264_CR114","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/10401239509149033","volume":"7","author":"G Tsai","year":"1995","unstructured":"Tsai G, Crisostomo G, Rosenblatt ML, et al.: Neuroleptic malignant syndrome associated with clozapine treatment. Annals of Clinical Psychiatry 7:91\u201395, 1995","journal-title":"Annals of Clinical Psychiatry"},{"key":"9264_CR115","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1345\/aph.18286","volume":"33","author":"JL Karagianis","year":"1999","unstructured":"Karagianis JL, Phillips LC, Hogan KP, et al.: Clozapine-associated neuroleptic malignant syndrome: Two new cases and a review of the literature. Annals of Pharmacotherapy 33:623\u2013630, 1999","journal-title":"Annals of Pharmacotherapy"},{"key":"9264_CR116","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1176\/ajp.154.10.1475","volume":"154","author":"M Newman","year":"1997","unstructured":"Newman M, Adityanjee, Jampala C: Atypical neuroleptic malignant syndrome associated with risperidone treatment (letter). American Journal of Psychiatry 154:1475, 1997","journal-title":"American Journal of Psychiatry"},{"key":"9264_CR117","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1177\/106002809603000713","volume":"30","author":"R Sharma","year":"1996","unstructured":"Sharma R, Trappler B, Ng YK, et al.: Risperidone-induced neuroleptic malignant syndrome. Annals of Pharmacotherapy 30:775\u2013778, 1996","journal-title":"Annals of Pharmacotherapy"},{"key":"9264_CR118","doi-asserted-by":"crossref","first-page":"448","DOI":"10.12968\/hosp.1999.60.6.1140","volume":"60","author":"J Edgar","year":"1999","unstructured":"Edgar J: Droperidol-induced neuroleptic malignant syndrome. Hospital Medicine 60:448\u2013450, 1999","journal-title":"Hospital Medicine"},{"key":"9264_CR119","first-page":"101","volume":"7","author":"PC So","year":"2001","unstructured":"So PC: Neuroleptic malignant syndrome induced by droperidol. Hong Kong Medical Journal 7:101\u2013103, 2001","journal-title":"Hong Kong Medical Journal"},{"key":"9264_CR120","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/106002808802200606","volume":"22","author":"AJ Wells","year":"1988","unstructured":"Wells AJ, Sommi RW, Crismon ML: Neuroleptic rechallenge after neuroleptic malignant syndrome: Case report and literature review. Drug Intelligence & Clinical Pharmacy 22:475\u2013480, 1988","journal-title":"Drug Intelligence & Clinical Pharmacy"},{"key":"9264_CR121","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1592\/phco.21.11.1003.34528","volume":"21","author":"CD Hatch","year":"2001","unstructured":"Hatch CD, Lund BC, Perry PJ: Failed challenge with quetiapine after neuroleptic malignant syndrome with conventional antipsychotic. Pharmacotherapy 21:1003\u20131006, 2001","journal-title":"Pharmacotherapy"},{"key":"9264_CR122","volume-title":"Use of Drugs in Psychiatry; the Evidence from Psychopharmacology","author":"JC Cookson","year":"2002","unstructured":"Cookson JC, Katona CLE, Taylor D: Use of Drugs in Psychiatry; the Evidence from Psychopharmacology, 5th edn. London, Gaskell, 2002","edition":"5"},{"key":"9264_CR123","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/archpsyc.61.8.781","volume":"61","author":"K Chang","year":"2004","unstructured":"Chang K, Adleman NE, Dienes K, et al.: Anomalous prefrontal-subcortical activation in familial pediatric bipolar disorder: A functional magnetic resonance imaging investigation. Archives General Psychiatry 61:781\u2013792, 2004","journal-title":"Archives General Psychiatry"},{"key":"9264_CR124","first-page":"627","volume":"35","author":"P Brieger","year":"2003","unstructured":"Brieger P, Reinelt Y: No recurrence of a neuroleptic malignant syndrome under quetiapine. Australian and New Zealand Journal of Psychiatry 35:627, 2003","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"key":"9264_CR125","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0006-3223(97)00450-2","volume":"43","author":"P Thomas","year":"1998","unstructured":"Thomas P, Maron M, Rascle C, et al.: Carbamazepine in the treatment of neuroleptic malignant syndrome. Biological Psychiatry 43:303\u2013305, 1998","journal-title":"Biological Psychiatry"},{"key":"9264_CR126","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1176\/appi.neuropsych.18.1.131","volume":"18","author":"RR Tadke","year":"2006","unstructured":"Tadke RR, Suryavanshi P: Use of intravenous valproate in a patient with neuroleptic malignant syndrome. Journal of Neuropsychiatry & Clinical Neurosciences 18:131\u2013132, 2006","journal-title":"Journal of Neuropsychiatry & Clinical Neurosciences"},{"key":"9264_CR127","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1017\/S1092852900013407","volume":"5","author":"A Francis","year":"2000","unstructured":"Francis A, Chandragiri S, Rizvi S, et al.: Is lorazepam a treatment for neuroleptic malignant syndrome? CNS Spectrums 5:54\u201357, 2000","journal-title":"CNS Spectrums"},{"key":"9264_CR128","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1007\/s00702-002-0762-z","volume":"109","author":"G Northoff","year":"2002","unstructured":"Northoff G: Catatonia and neuroleptic malignant syndrome: psychopathology and pathophysiology. Journal of Neural Transmission 109:1453\u20131467, 2002","journal-title":"Journal of Neural Transmission"},{"key":"9264_CR129","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1176\/ajp.154.6.882","volume":"154","author":"H Miyaoka","year":"1997","unstructured":"Miyaoka H, Shishikura K, Otsubo T: Diazepam-responsive neuroleptic malignant syndrome: A diagnostic subtype? American Journal of Psychiatry 154:882, 1997","journal-title":"American Journal of Psychiatry"},{"key":"9264_CR130","first-page":"2155","volume":"89","author":"D Kasantikul","year":"2007","unstructured":"Kasantikul D, Kanchanatawan B: Neuroleptic malignant syndrome: A review and report of six cases. Journal of the Medical Association of Thailand\u2019s 89:2155\u20132160, 2007","journal-title":"Journal of the Medical Association of Thailand\u2019s"},{"key":"9264_CR131","first-page":"764","volume":"45","author":"R Waneen","year":"2000","unstructured":"al-Waneen R: Neuroleptic malignant syndrome associated with quetiapine. Canadian Journal of Psychiatry 45:764\u2013765, 2000","journal-title":"Canadian Journal of Psychiatry"}],"container-title":["Psychiatric Quarterly"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11126-013-9264-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11126-013-9264-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11126-013-9264-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T20:17:06Z","timestamp":1688242626000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11126-013-9264-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,18]]},"references-count":131,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["9264"],"URL":"https:\/\/doi.org\/10.1007\/s11126-013-9264-4","relation":{},"ISSN":["0033-2720","1573-6709"],"issn-type":[{"value":"0033-2720","type":"print"},{"value":"1573-6709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,18]]}}}